Expression of NRP-1 and NRP-2 in Endometrial Cancer

Author(s): Marcin Oplawski*, Konrad Dziobek, Beniamin Grabarek, Nikola Zmarzły, Dariusz Dąbruś, Piotr Januszyk, Ryszard Brus, Barbara Tomala, Dariusz Boroń.

Journal Name: Current Pharmaceutical Biotechnology

Volume 20 , Issue 3 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Background: Neuropilins (NRPs) participate in many processes related to cancer development such as angiogenesis, lymphangiogenesis and metastasis. Although endometrial cancer is one of the most common gynecological cancers, it has not been studied in terms of NRPs expression.

Objective: The aim of this study was to investigate the potential utility of NRPs as important factors in the diagnosis and treatment of endometrial cancer.

Methods: Our study consisted of 45 women diagnosed with endometrial cancer at the following degrees of histological differentiation: G1, 17; G2, 15; G3, 13 cases. The control group included 15 women without neoplastic changes. The immunohistochemical reactions were evaluated using light microscopy.

Results: We did not detect the expression of NRP-1 and NRP-2 in the control group. NRP-1 expression was found exclusively in cancer cells. It was higher in G2 and G3 and reached about 190% of G1. NRP-2 expression was observed in the endothelium and was similar across all three cancer grades. In cancer cells, NRP-2 expression increased with the degree of histological differentiation.

Conclusion: NRP1 and NRP2 are candidates for complementary diagnostic molecular markers and promising new targets for molecular, personalized anticancer therapies.

Keywords: Tumor growth, endometrial cancer, neuropilins (NRPs), molecular marker, endothelium, cancer grade.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [254 - 260]
Pages: 7
DOI: 10.2174/1389201020666190219121602

Article Metrics

PDF: 12